Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance

Cell Cycle

Volumn 6, Issue 8, 2007, Pages 888-894

  Steinberg, Gregory R ^a  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

ACC; AMPK; Macrophage; Protein phosphatase 2C; Skeletal muscle; TNF

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

FATTY ACID METABOLISM; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC DISORDER; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 34247489726     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.8.4135     Document Type: Review

References (98)

1. Steinberg GR, Michell BJ, van Denderen BJ, Watt MJ, Carey AL, Fam BC, Andrikopoulos S, Proietto J, Gorgun CZ, Carling D, Hotamisligil GS, Febbraio MA, Kay TW, Kemp BE. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of amp-kinase signaling. Cell Metab 2006; 4:465-74.
2. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItalliw TB. Annual deaths attributable to obesity in the united states. JAMA 1999; 282:1530-1538.
3. Organization WH. The world health report 2002. Reducing Risks. Geneva: Promoting Healthy Life World Health Organization, 2002.
4. Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest 2006; 116:1767-1775.
5. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance: Elevated serine/threonine phosphorylation of irs-1 and irs-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 272:29911-8.
6. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (irs-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277:50230-50236.
7. Li Y, Soos TJ, Li X, Wu J, DeGennaro M, Sun X, Littman DR, Birnbaum MJ, Polakiewicz RD. Protein kinase c {theta} inhibits insulin signaling by phosphorylating irs1 at ser1101. J Biol Chem 2004; 279:45304-45307.
8. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa b kinase complex. J Biol Chem 2002; 277:48115-21.
9. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-jun nh(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of ser(307). J Biol Chem 2000; 275:9047-54.
10. Jamieson E, Chong MM, Steinberg GR, Jovanovska V, Fam BC, Bullen DV, Chen Y, Kemp BE, Proietto J, Kay TW, Andrikopoulos S. Socs1 deficiency enhances hepatic insulin signaling. J Biol Chem 2005; 280:31516-21.
11. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (socs-1) and socs-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24:5434-5446.
12. Shi H, Cave B, Inouye K, Bjorbaek C, Flier JS. Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 2006; 55:699-707.
13. Bell KS, Schmitz-Peiffer C, Lim-Fraser M, Biden TJ, Cooney GJ, Kraegen EW. Acute reversal of lipid-induced muscle insulin resistance is associated with rapid alteration in pkc-theta localization. Am J Physiol 2000; 279:E1196-1201.
14. Itani SI, Zhou Q, Pories WJ, MacDonald KG, Dohm GL. Involvement of protein kinase c in human skeletal muscle insulin resistance in obesity. Diabetes 2000; 49:1353-1358.
15. Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O'Brien WR, Littman DR, Shulman GI. Pkc-{theta} knockout mice are protected from fat-induced insulin resistance. J Clin Invest 2004; 114:823-827.
16. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of ikkbeta. Science 2001; 293:1673-1677.
17. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. Ikk-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11:191-8.
18. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Teoman Uysal K, Maeda K, Karin M, Hotamisligil GS. A central role for jnk is obesity and insulin resistance. Nature 2002; 420:333-336.
19. Steinberg GR, Smith AC, Wormald S, Malenfant P, Collier C, Dyck DJ. Endurance training partially reverses dietary-induced leptin resistance in rodent skeletal muscle. Am J Physiol Endocrinol Metab 2004; 286:E57-63.
20. Steinberg GR, McAinch AJ, Chen MB, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE. The suppressor of cytokine signaling 3 (socs3) inhibits leptin activation of amp-kinase in cultured skeletal muscle of obese humans. J Clin Endocrinol Metab 2006.
21. Hotamisligil G, Shargill N, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
22. Hotamisligil G, Murray D, Choy L, Spiegelman B. Tumor necrosis factor {alpha} inhibits signaling from the insulin receptor. Proc Natl Acad Sci 1994; 91:4854-4858.
23. Hotamisligil GS, Murray D, Choy L, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci 1994; 91:4854-4858.
24. Hotamisligil G, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94:1543-1549.
25. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95:2409-2415.
26. Hotamisligil GS, Peraldi P, Budavari A, Ellis BA, White MF, Spiegelman BM. Irs-1 mediated inhibition of insulin receptor tyrosine kinase activity in tnf-alpha- and obesity-induced insulin resistance. Science 1996; 271:665-668.
27. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-53.
28. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001; 52:119-23.
29. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K, Yano Y. Serum levels of tumor necrosis factor-alpha are increased in obese patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83:859-62.
30. Zinman B, Hanley AJG, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84:272-278.
31. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of tnfalpha by human muscle: Relationship to insulin resistance. J Clin Invest 1996; 97:1111-1116.
32. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol 2001; 280:E745-E751.
33. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-{alpha} induces skeletal muscle insulin resistance in healthy human subjects via inhibition of akt substrate 160 phosphorylation. Diabetes 2005; 54:2939-45.
34. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking tnf-alpha function. Nature 1997; 389:610-4.
35. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-tnf-alpha antibody (cdp571) on insulin sensitivity and glycemic control in patients with niddm. Diabetes 1996; 45:881-885.
36. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:83-6.
37. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
38. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110:1564-71.
39. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase c, and ikappab-alpha. Diabetes 2002; 51:2005-2011.
40. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, Sizemore N, Hwang DH. Reciprocal modulation of toll-like receptor-4 signaling pathways involving myd88 and phosphatidylinositol 3-kinase/akt by saturated and polyunsaturated fatty acids. J Biol Chem 2003; 278:37041-51.
41. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. Tlr4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116:3015-25.
42. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein ap2 protects mice deficient in apolipoprotein e against atherosclerosis. Nat Med 2001; 7:699-705.
43. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1:107-19.
44. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of ikk-beta and nf-kappab. Nat Med 2005; 11:183-90.
45. Bode JG, Nimmesgern A, Schmitz J, Schaper F, Schmitt M, Frisch W, Haussinger D, Heinrich PC, Graeve L. Lps and tnf[alpha] induce socs3 mrna and inhibit il-6-induced activation of stat3 in macrophages. FEBS Letters 1999; 463:365-370.
46. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-7.
47. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-176.
48. Gaster M, Rustan AC, Aas V, Beck-Nielsen H. Reduced lipid oxidation in skeletal muscle from type 2 diabetic subjects may be of genetic origin: Evidence from cultured myotubes. Diabetes 2004; 53:542-548.
49. Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation 1994; 94:2349-2356.
50. Hulver MW, Berggren JR, Cortright RN, Dudek RW, Thompson RP, Pories WJ, MacDonald KG, Cline GW, Shulman GI, Dohm GL, Houmard JA. Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab 2003; 284:E741-732.
51. Steinberg GR, Parolin ML, Heigenhauser GJ, Dyck DJ. Leptin increases fa oxidation in lean but not obese human skeletal muscle: Evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002; 283:E187-92.
52. Steinberg GR, Macaulay SL, Febbraio MA, Kemp BE. Amp-kinase the fat controller of the energy railroad. Can J Phys Pharm 2006, (in press).
53. Mahlapuu M, Johansson C, Lindgren K, Hjalm G, Barnes BR, Krook A, Zierath JR, Andersson L, Marklund S. Expression profiling of the {gamma}-subunit isoforms of amp-activated protein kinase suggests a major role for {gamma}3 in white skeletal muscle. Am J Physiol Endocrinol Metab 2004; 286:E194-200.
54. Wojtaszewski JFP, Birk JB, Frøsig C, Holten M, Pilegaard H, Dela F. 5′amp activated protein kinase expression in human skeletal muscle: Effects of strength training and type 2 diabetes. J Physiol 2005; 564.2:563-573.
55. Sakamoto K, McCarthy A, Smith D, Green KA, Grahame Hardie D, Ashworth A, Alessi DR. Deficiency of lkb1 in skeletal muscle prevents ampk activation and glucose uptake during contraction. Embo J 2005; 24:1810-20.
56. Davies SP, Helps NR, Cohen PT, Hardie DG. 5′-amp inhibits dephosphorylation, as well as promoting phosphorylation, of the amp-activated protein kinase: Studies using bacterially expressed human protein phosphatase-2c alpha and native bovine protein phosphatase-2ac. FEBS Lett 1995; 377:421-425.
57. Scott JW, Ross FA, Liu JK, Hardie DG. Regulation of amp-activated protein kinase by a pseudosubstrate sequence on the gamma subunit. Embo J 2007.
58. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, Scullion GA, Norman DG, Hardie DG. Cbs domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004; 113:274-84.
59. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for amp activation of the amp-activated protein kinase cascade. Biochem J 2006.
60. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating amp-activated protein kinase. Nature 2002; 415:339-343.
61. Steinberg GR, Rush JWE, Dyck DJ. Ampk expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. Am J Physiol Endocrinol Metab 2003; 284: E648-654.
62. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating amp-activated protein kinase. Nat Med 2002; 8:1288-1295.
63. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by acrp30 globular domain: Acetyl-coa carboxylase inhibition and amp-activated protein kinase activation. Proc Natl Acad Sci USA 2002; 99:16309-16313.
64. Kelly M, Keller C, Aviluea PR, Keller P, Luo Z, Ziang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB. Ampk activity is diminished in tissues of il-6 knockout mice: The effect of exercise. Biochem Biophys Res Commun 2004; 320:449-454.
65. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Il-6 increases insulin stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via ampk. Diabetes 2006; 55:2688-2697.
66. Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR. Cntf reverses obesity-induced insulin resistance by activating skeletal muscle ampk. Nat Med 2006; 12:541-548.
67. Satoh H, Nguyen MTA, Miles PDG, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic "Hyper-resistinemia" Leads to in vivo insulin resistance in normal rats. J Clin Invest 2004; 114:224-231.
68. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased malonyl-coa levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 2006; 55:2277-85.
69. Yu X, McCorkle S, Wang M, Lee Y, Li J, Saha AK, Unger RH, Ruderman NB. Leptinomimetic effects of the amp kinase activator aicar in leptin-resistant rats: Prevention of diabetes and ectopic lipid deposition. Diabetaologia 2004; 47:2012-2021.
70. Barnes BR, Ryder JW, Steiler TL, Fryer LG, Carling D, Zierath JR. Isoform specific regulation of 5' amp-activated protein kinase in skeletal muscle from obese zucker (fa/fa) rats in response to contraction. Diabetes 2002; 51:2703-2708.
71. Steinberg GR, Smith AC, van Denderen BJW, Chen Z, Murthy S, Campbell DJ, Heigenhauser GJF, Dyck DJ, Kemp BE. Amp-activated protein kinase is not down-regulated in human skeletal muscle of obese females. J Clin Endocrinol Metab 2004; 89:4575-4580.
72. Hawley S, Boudeau J, Reid J, Mustard K, Udd L, Makela T, Alessi D, Hardie DG. Complexes between the lkb1 tumor suppressor, stradalpha/beta and mo25alpha/beta are upstream kinases in the amp-activated protein kinase cascade. Journal of Biology 2003; 2:28.
73. Lizcano JM, Olga Göransson, Rachel Toth, Maria Deak, Nick A Morrice, Jérôme Boudeau, Simon A Hawley, Lina Udd, Tomi P Mäkelä, Hardie DG, Alessi DR. Lkb1 is a master kinase that activates 13 kinases of the ampk subfamily, including mark/par-1. EMBO J 2004; 23:833-843.
74. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC. Inaugural article: The tumor suppressor lkb1 kinase directly activates amp-activated kinase and regulates apoptosis in response to energy stress. PNAS 2004; 101:3329-3335.
75. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. Lkb1 is the upstream kinase in the amp-activated protein kinase cascade. Curr Biol 2003; 13:2004-2008.
76. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277:1531-1537.
77. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. Ampk phosphorylates irs-1 on ser789 in mouse c2c12 myotubes in response to 5-aminoimidazole-4- carboxamide riboside. J Biol Chem 2001; 276:46912-46916.
78. Thong FS, Bilan PJ, Klip A. The rab gtpase-activating protein as160 integrates akt, protein kinase c, and amp-activated protein kinase signals regulating glut4 traffic. Diabetes 2007; 56:414-23.
79. Arias EB, Kim J, Funai K, Cartee GD. Prior exercise increases phosphorylation of akt substrate of 160 kda (as160) in rat skeletal muscle. Am J Physiol Endocrinol Metab 2006.
80. Treebak JT, Birk JB, Rose AJ, Kiens B, Richter EA, Wojtaszewski JF. As160 phosphorylation is associated with activation of {alpha}2{beta}2{gamma}1 but not {alpha}2{beta}2{gamma}3 ampk trimeric complex in skeletal muscle during exercise in humans. Am J Physiol Endocrinol Metab 2006.
81. Kramer HF, Witczak CA, Fujii N, Jessen N, Taylor EB, Arnolds DE, Sakamoto K, Hirshman MF, Goodyear LJ. Distinct signals regulate as160 phosphorylation in response to insulin, aicar, and contraction in mouse skeletal muscle. Diabetes 2006; 55:2067-76.
82. Treebak JT, Glund S, Deshmukh A, Klein DK, Long YC, Jensen TE, Jorgensen SB, Viollet B, Andersson L, Neumann D, Wallimann T, Richter EA, Chibalin AV, Zierath JR, Wojtaszewski JF. Ampk-mediated as160 phosphorylation in skeletal muscle is dependent on ampk catalytic and regulatory subunits. Diabetes 2006; 55:2051-8.
83. Cacicedo JM, Yagihashi N, Keaney Jr JF, Ruderman NB, Ido Y. Ampk inhibits fatty acid-induced increases in nf-kappab transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 324:1204-9.
84. Miles PDG, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky J. Tnf-alpha-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46:1678-1683.
85. Ruan H, Miles PDG, Ladd CM, Ross K, Golub TR, Olefsky JM, Lodish HF. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-{alpha}: Implications for insulin resistance. Diabetes 2002; 51:3176-3188.
86. Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE, Steinberg GR. Impaired activation of amp-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab 2005; 90:3665-3672.
87. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
88. Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, Lazar MA, Ahima RS. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 2006; 55:3083-90.
89. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J. Activation of peroxisome proliferator-activated receptor {delta} induces fatty acid {beta}-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci 2003; 100:15924-15929.
90. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350:664-71.
91. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. Amp kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci 2002; 99:15983-15987.
92. Jorgensen SB, Wojtaszewski JF, Viollet B, Andreelli F, Birk JB, Hellsten Y, Schjerling P, Vaulont S, Neufer PD, Richter EA, Pilegaard H. Effects of alpha-ampk knockout on exercise-induced gene activation in mouse skeletal muscle. Faseb J 2005; 19:1146-1148.
93. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate amp- activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277:25226-32.
94. Lessard SJ, Chen ZP, Watt MJ, Hashem M, Reid J, Febbraio MA, Kemp BE, Hawley JA. Chronic rosiglitazone treatment restores ampkalpha2 activity in insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 2006; 290:E251-E257.
95. Jiang C, Ting AT, Seed B. Ppar-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
96. Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, Kawahara J, Ueno E, Sasaoka T, Ishibashi O, Kobayashi M. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes 2001; 50:1083-92.
97. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, Straubhaar J, Czech MP, Corvera S. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004; 114:1281-9.
98. Civitarese AE, Ukropcova B, Carling S, Hulver M, DeFronzo RA, Mandarino L, Ravussin E, Smith SR. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 2006; 4:75-87.